Dancann Pharma
DanCann Pharma A/S is a Danish biopharmaceutical company that distributed standardized medicinal cannabis products (Bedrocan, Bediol, Bedica, Bedrolite, Bedrobinol) to Danish pharmacies and now, following the November 2025 CannGros divestment, operates as a holding entity with an ~11.5% stake in Stenocare and a developing OTC cannabis subsidiary.
- Company typePublic
- Founded2018
- HeadquartersAnsager, Denmark
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Dancann Pharma does
DanCann Pharma A/S is a Danish biopharmaceutical company founded in March 2018 by Jeppe Krog Rasmussen, headquartered in Ansager, Denmark, and listed on Sweden's Spotlight Stock Market (SS: DANCAN) since November 2020. The company historically operated across the full medicinal cannabis value chain — from EU-GMP-certified manufacturing at its BP1 facility, through importation and repackaging via its now-divested subsidiary CannGros ApS, to wholesale distribution to all Danish pharmacies — and held a portfolio of five standardized cannabis medicines (Bedrocan, Bediol, Bedica, Bedrolite, Bedrobinol) covering different cultivar profiles and a CBD-based formulation. Following an August 2023 strategic realignment and the November 2025 divestment of CannGros to Stenocare A/S in exchange for 5 million Stenocare shares (giving DanCann an ~11.5% stake), the operating footprint has materially contracted: the BP1 manufacturing site is under conditional sale (potential EUR 0.75M proceeds), the company is voluntarily delisting from Spotlight with last trading day expected January 22, 2026, and the new OTC Group ApS subsidiary (December 2024) signals a pivot toward over-the-counter preparations such as VitaZynq.
The business model is wholesale pharmaceutical distribution under Denmark's medicinal cannabis framework, with revenue generated from product sales to pharmacies (FY2024 net sales of DKK 7.76M, +27.8% YoY) at approximately DKK 250 per five-gram unit under the Danish reimbursement scheme, plus a developing OTC line. Go-to-market is B2B through Danish wholesalers serving pharmacies, with a separate practitioner-education channel (healthcare professional portal) to drive prescription demand. Customers are Danish pharmacies as direct buyers and, indirectly, chronic-pain patients (~1.3M Danes, 500,000 on opioid regimens) accessing treatment via physician prescription under the now-permanent Danish medicinal cannabis program. As of late 2025, the company's revenue base has been substantially transferred to Stenocare, and forward economics will depend on OTC Group buildout, residual licensing/IP economics, and value realization from the ~11.5% Stenocare equity stake.
Dancann Pharma firmographics
Firmographics- Name
- Dancann Pharma
- Legal name
- DanCann Pharma A/S
- Website
- https://dancann.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DanCann Pharma A/S is a Danish biopharmaceutical company that distributed standardized medicinal cannabis products (Bedrocan, Bediol, Bedica, Bedrolite, Bedrobinol) to Danish pharmacies and now, following the November 2025 CannGros divestment, operates as a holding entity with an ~11.5% stake in Stenocare and a developing OTC cannabis subsidiary.
- Ownership category
- akta.pro rank
Dancann Pharma industry classification
Industry- Product category
- Medicinal Cannabis Pharmaceuticals
- NAICS
- Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Retail-Drug Stores And Proprietary Stores (5912)
- akta.pro primary industry
- Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)
Keywords
Where Dancann Pharma is headquartered
LocationHeadquarters
- HQ city
- Ansager
- HQ country
- Denmark
- HQ region
- Europe
Offices2 records
Markets served
Dancann Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Medicinal Cannabis Product Sales: DanCann Pharma generates revenue through the sale of medicinal cannabis products (Bedrocan, Bediol, Bedica, Bedrolite, Bedrobinol) to Danish pharmacies. The company reported net sales of DKK 7.76 million in 2024, up 27.8% year-over-year.
- Distribution and Sourcing Services: Following the 2023 strategic realignment, the company focuses on sourcing, distribution, and sales within the Danish market through its CannGros subsidiary. Revenue is generated from importation, repackaging, warehousing, logistics, and distribution of cannabis products to pharmacies.
- Shareholdings in Stenocare: Following the sale of CannGros to Stenocare A/S in November 2025, DanCann Pharma received 5,000,000 Stenocare shares (approximately 11.5% stake) as consideration, creating potential for equity value realization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Medicinal cannabis products subsidized at approximately DKK 250 per five-gram unit |
| Unit Pricing | Pay-as-you-go | Prescription-based medicinal cannabis through pharmacies |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Dancann Pharma product offering
Product offeringCore offering
DanCann Pharma manufactures and distributes standardized medicinal cannabis products for the Danish market, including flos and granule formulations (Bedrocan, Bedica, Bediol, Bedrolite, Bedrobinol) and oral extracts. The company sources, imports, repackages, and distributes these cannabis-based medicines to Danish pharmacies through its subsidiary CannGros ApS under the Danish Pilot Programme for Medicinal Cannabis. It also operates an EU-GMP certified production facility (BP1) and is developing OTC cannabinoid preparations through its OTC Group ApS subsidiary.
Product overview
DanCann Pharma is a Danish biopharmaceutical company powered by cannabinoids, operating primarily as a distributor and manufacturer of medicinal cannabis products in Denmark. The company conducts its Danish operations through its subsidiary CannGros ApS, which handles importation, repackaging, warehousing, and distribution of cannabis products to all pharmacies across Denmark. The core product portfolio includes standardized cannabinoid medicines: Bedrocan®, Bedica®, Bediol®, Bedrolite®, and Bedrobinol® (flos/flower products and extracts). The company also has pipeline products including Bedrostract® (oral extract) and development-stage products like mouth spray formulations. In December 2024, the company established OTC Group ApS to expand into OTC preparations. The company's strategy (Maturity2028) has shifted toward distribution, sourcing, and import of medicinal cannabis following strategic realignment. Key recent developments include the sale of CannGros to Stenocare (November 2025) and plans to divest the BP1 production facility.
Differentiator
Problem solved
Functional benefit
Products and services
- Bedrocan Standardized medicinal cannabis flower (flos) product, the brand name for the cultivar Cannabis Sativa L. 'Afina', distributed through the Danish Pilot Programme for patients with a valid doctor prescription.
- Bedica Standardized medicinal cannabis flower (flos) product, the brand name for the indica cultivar Cannabis Sativa L. 'Talea', distributed through the Danish Pilot Programme.
- Bediol Standardized medicinal cannabis product, the brand name for the cultivar Cannabis Sativa L. 'Elida', distributed through the Danish Pilot Programme.
- Bedrolite Standardized CBD-based medicinal cannabis product, the brand name for the cultivar Cannabis Sativa L. 'Rensina', approved for the Danish medicinal cannabis market.
- Bedrobinol Standardized medicinal cannabis flos product, the brand name for the cultivar Cannabis Sativa L. 'Ludina', approved for the Danish medicinal cannabis market.
- VitaZynq Full-spectrum botanical (phyto) extract derived from Cannabis Sativa L., marketed as an over-the-counter (OTC) preparation through the OTC Group ApS subsidiary.
Quantifiable outcome
- Revenue growth of 27.8% YoY in 2024 (DKK 6.07M to DKK 7.76M)
- +4 more outcomes
Companies that use Dancann Pharma
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Dancann Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Dancann Pharma partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- StenoCare A/ScoreDanCann Pharma divested its wholly-owned subsidiary CannGros ApS to StenoCare A/S through a share-for-share exchange. Stenocare issued 5,000,000 new shares to DanCann as consideration. This strategic transaction converts CannGros from an operating subsidiary into liquid listed equity, making DanCann one of the largest single shareholders in Stenocare (approximately 11.5%).
- Danish Medicines AgencycoreDanCann Pharma received Danish Medicines Agency approval to launch Bedrolite and Bedrobinol products, expanding its medical cannabis portfolio to five offerings ahead of Denmark's permanent medical cannabis program.
- Medicinsk Cannabis Industri (MCI)minorDanCann Pharma is represented through its membership in MCI, where CEO Jeppe Krog Rasmussen serves as Vice Chairman of the interest organization. MCI serves as a reference group for medicinal cannabis extended through 2025-2026.
- CannGros ApScoreDanCann Pharma acquired CannGros ApS in October 2021 as a strategic move to overtake distribution of Bedrocan, Bediol, and Bedica products to all pharmacies in Denmark. CannGros was subsequently sold to Stenocare in November 2025.
- Danish Medicines AgencycoreDanCann secured the first license from the Danish Medicines Agency under the Development Scheme for handling cannabis for medical purposes, becoming among the first companies granted such a license.
Scale indicators12 records
Recent moves10 records
Expansion highlights5 records
Dancann Pharma competitors and assessment
Company assessmentRegional players
- Ayruma AG (formerly Northern Green Canada / CC Pharma): European-focused cannabis pharmaceutical distribution company with German pharmacy distribution roots; comparable B2B distribution of medical cannabis to retail pharmacies under regulatory schemes.
Emerging players
- Panaxia Labs Israel Industries: Israeli manufacturer of pharmaceutical-grade cannabinoid medicines with EU-GMP compliant production; comparable cannabis-based pharmaceutical formulations and dosage-form development focus.
- MediPharm Labs Corp. Canadian pharmaceutical-grade cannabis producer with EU-GMP certification supplying wholesale cannabis APIs and finished dose formats to European distributors; comparable role in the medicinal cannabis supply chain.
Broad incumbents
- Aurora Cannabis Inc. Canadian global cannabis company with European medical cannabis operations including cultivation, manufacturing and distribution of EU-GMP certified products across multiple European markets including Denmark-adjacent geographies.
- Canopy Growth Corporation: Canadian global cannabis incumbent with Spectrum Therapeutics medical cannabis portfolio distributed in European markets, including Germany and other countries following similar reimbursement pathways.
- Tilray Brands Inc. Large Canadian-headquartered global cannabis player with established EU medical cannabis operations including cultivation in Portugal and Germany, distributing branded medical cannabis products through European pharmacy channels.
Direct peers
- Cantourage GmbH: German medicinal cannabis distribution platform that partners with international producers to bring standardized cannabis medicines to German pharmacies. Highly comparable GTM: B2B pharmacy distribution of third-party-produced standardized cannabis medicines.
- Demecan GmbH: German producer and distributor of medical cannabis flowers and extracts under EU-GMP, serving a parallel pharmaceutical-distribution model in Europe's largest medicinal cannabis pilot market.
- Bedrocan BV: Dutch producer of standardized medicinal cannabis flos that supplies the Bedrocan, Bediol, Bedica, Bedrolite and Bedrobinol products DanCann distributes. Same product family, same regulatory pathway (EU-GMP), same patient base across Europe.
- Stenocare A/S: Danish medicinal cannabis company listed on Spotlight Stock Market; acquired DanCann's CannGros subsidiary in November 2025, making DanCann an 11.5% shareholder. Operates in the same Danish pilot/permanent programme with overlapping product portfolios including the patented ASTRUM oil.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Dancann Pharma social profiles
Digital presenceDancann Pharma compliance and trust
Trust signalCompliance3 records
Dancann Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dancann Pharma leadership team
Management profileNumber of profiles
Profiles4 records
Dancann Pharma subsidiaries and ownership
Company hierarchySubsidiaries2 records
Dancann Pharma funding detail
Funding detailFunding overview
Funding rounds6 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dancann Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dancann Pharma
What does Dancann Pharma do?
DanCann Pharma manufactures and distributes standardized medicinal cannabis products for the Danish market, including flos and granule formulations (Bedrocan, Bedica, Bediol, Bedrolite, Bedrobinol) and oral extracts. The company sources, imports, repackages, and distributes these cannabis-based medicines to Danish pharmacies through its subsidiary CannGros ApS under the Danish Pilot Programme for Medicinal Cannabis. It also operates an EU-GMP certified production facility (BP1) and is developing OTC cannabinoid preparations through its OTC Group ApS subsidiary.
Is Dancann Pharma a public or private company?
Dancann Pharma is a public company. It is classified as public and is currently operating.
When was Dancann Pharma founded?
Dancann Pharma was founded in 2018. It employs 11 to 50 people.
Where is Dancann Pharma based?
Dancann Pharma is headquartered in Ansager, Denmark, in the Europe region.
How does Dancann Pharma make money?
Three revenue lines are on record. Medicinal Cannabis Product Sales are the primary driver. The others are distribution and Sourcing Services and shareholdings in Stenocare.
Who are Dancann Pharma's main competitors?
Ayruma AG (formerly Northern Green Canada / CC Pharma) is listed as a regional player. Emerging players are Panaxia Labs Israel Industries and MediPharm Labs Corp.. Broad incumbents are Aurora Cannabis Inc., Canopy Growth Corporation and Tilray Brands Inc.. Direct peers are Cantourage GmbH, Demecan GmbH, Bedrocan BV and Stenocare A/S.
Does Dancann Pharma have an API?
No public API is recorded for Dancann Pharma.
What industry is Dancann Pharma in?
Dancann Pharma's product category is Medicinal Cannabis Pharmaceuticals. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services). Its NAICS code is 325411 and its SIC code is 2833.